• Retrospective cohort study
• ≥ 18 years of age
• Severe COVID-19 infection
• Evaluation of 28-day mortality in heparin and non-heparin users
• 48.5% comorbid hypertension and/or heart disease
•  N = 99 heparin
•  N = 350 no heparin